ATEA PHARMACEUTICALS INC (AVIR) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:AVIR • US04683R1068

4.14 USD
-0.01 (-0.24%)
At close: Feb 9, 2026
4.14 USD
0 (0%)
After Hours: 2/9/2026, 6:44:26 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

AVIR gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 191 industry peers in the Pharmaceuticals industry. AVIR has a great financial health rating, but its profitability evaluates not so good. AVIR does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • AVIR had negative earnings in the past year.
  • In the past year AVIR has reported a negative cash flow from operations.
  • In the past 5 years AVIR reported 4 times negative net income.
  • AVIR had negative operating cash flow in 4 of the past 5 years.
AVIR Yearly Net Income VS EBIT VS OCF VS FCFAVIR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

1.2 Ratios

  • With a Return On Assets value of -42.87%, AVIR perfoms like the industry average, outperforming 41.36% of the companies in the same industry.
  • AVIR has a Return On Equity (-46.56%) which is in line with its industry peers.
Industry RankSector Rank
ROA -42.87%
ROE -46.56%
ROIC N/A
ROA(3y)-25.47%
ROA(5y)-12.4%
ROE(3y)-26.96%
ROE(5y)-13.16%
ROIC(3y)N/A
ROIC(5y)N/A
AVIR Yearly ROA, ROE, ROICAVIR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 20 -20 -40 -60

1.3 Margins

  • AVIR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AVIR Yearly Profit, Operating, Gross MarginsAVIR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. Health

2.1 Basic Checks

  • Compared to 1 year ago, AVIR has more shares outstanding
  • Compared to 5 years ago, AVIR has more shares outstanding
  • AVIR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
AVIR Yearly Shares OutstandingAVIR Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
AVIR Yearly Total Debt VS Total AssetsAVIR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

  • AVIR has an Altman-Z score of 4.77. This indicates that AVIR is financially healthy and has little risk of bankruptcy at the moment.
  • With a decent Altman-Z score value of 4.77, AVIR is doing good in the industry, outperforming 73.30% of the companies in the same industry.
  • There is no outstanding debt for AVIR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 4.77
ROIC/WACCN/A
WACCN/A
AVIR Yearly LT Debt VS Equity VS FCFAVIR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

  • A Current Ratio of 16.66 indicates that AVIR has no problem at all paying its short term obligations.
  • The Current ratio of AVIR (16.66) is better than 86.91% of its industry peers.
  • A Quick Ratio of 16.66 indicates that AVIR has no problem at all paying its short term obligations.
  • AVIR has a better Quick ratio (16.66) than 86.91% of its industry peers.
Industry RankSector Rank
Current Ratio 16.66
Quick Ratio 16.66
AVIR Yearly Current Assets VS Current LiabilitesAVIR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an nice 14.49% over the past year.
EPS 1Y (TTM)14.49%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-43.24%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 6.84% on average over the next years.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y3.1%
EPS Next 2Y1.54%
EPS Next 3Y6.84%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
AVIR Yearly Revenue VS EstimatesAVIR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2027 100M 200M 300M
AVIR Yearly EPS VS EstimatesAVIR Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 0 1 -1

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for AVIR. In the last year negative earnings were reported.
  • Also next year AVIR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AVIR Price Earnings VS Forward Price EarningsAVIR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AVIR Per share dataAVIR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y1.54%
EPS Next 3Y6.84%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for AVIR!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ATEA PHARMACEUTICALS INC

NASDAQ:AVIR (2/9/2026, 6:44:26 PM)

After market: 4.14 0 (0%)

4.14

-0.01 (-0.24%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-12
Earnings (Next)03-03
Inst Owners69.11%
Inst Owner Change-1.63%
Ins Owners5.41%
Ins Owner Change15.89%
Market Cap323.46M
Revenue(TTM)N/A
Net Income(TTM)-147.03M
Analysts82.22
Price Target6.12 (47.83%)
Short Float %10.73%
Short Ratio16.79
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-11.02%
Min EPS beat(2)-18.09%
Max EPS beat(2)-3.95%
EPS beat(4)1
Avg EPS beat(4)-5.92%
Min EPS beat(4)-18.09%
Max EPS beat(4)4.35%
EPS beat(8)4
Avg EPS beat(8)3.44%
EPS beat(12)8
Avg EPS beat(12)8.06%
EPS beat(16)12
Avg EPS beat(16)56.61%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-23.26%
EPS NY rev (1m)0%
EPS NY rev (3m)-10.47%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.02
P/tB 1.02
EV/EBITDA N/A
EPS(TTM)-1.77
EYN/A
EPS(NY)-1.94
Fwd EYN/A
FCF(TTM)-1.72
FCFYN/A
OCF(TTM)-1.72
OCFYN/A
SpS0
BVpS4.04
TBVpS4.04
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -42.87%
ROE -46.56%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-25.47%
ROA(5y)-12.4%
ROE(3y)-26.96%
ROE(5y)-13.16%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 16.66
Quick Ratio 16.66
Altman-Z 4.77
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)14.49%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-43.24%
EPS Next Y3.1%
EPS Next 2Y1.54%
EPS Next 3Y6.84%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-26.63%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year27.88%
EBIT Next 3Y14.82%
EBIT Next 5YN/A
FCF growth 1Y-57.52%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-57.52%
OCF growth 3YN/A
OCF growth 5YN/A

ATEA PHARMACEUTICALS INC / AVIR FAQ

What is the fundamental rating for AVIR stock?

ChartMill assigns a fundamental rating of 3 / 10 to AVIR.


What is the valuation status of ATEA PHARMACEUTICALS INC (AVIR) stock?

ChartMill assigns a valuation rating of 0 / 10 to ATEA PHARMACEUTICALS INC (AVIR). This can be considered as Overvalued.


How profitable is ATEA PHARMACEUTICALS INC (AVIR) stock?

ATEA PHARMACEUTICALS INC (AVIR) has a profitability rating of 1 / 10.


What is the earnings growth outlook for ATEA PHARMACEUTICALS INC?

The Earnings per Share (EPS) of ATEA PHARMACEUTICALS INC (AVIR) is expected to grow by 3.1% in the next year.